Physician profile
James C Ramicone
NPI 1366481830
$11,513.30
in general payments reported to CMS, 2019-2025
29 companies · $1,039 in 2025
The $1,039 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $73.82 · 2021: $767 · 2022: $3,141 · 2023: $1,912 · 2024: $2,294 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868 · Travel and Lodging: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.41 |
| Travel and Lodging | $1,375.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,065.07 | 2019-2025 | Aveir, Advisor, Ensite |
| Medtronic Vascular, INC. | $1,968.30 | 2019 | |
| Boston Scientific Corporation | $1,708.24 | 2019-2025 | General - Therapies, Watchman Access System, Farapulse |
| Atricure, INC. | $496.42 | 2021-2023 | |
| Biosense Webster, INC. | $426.31 | 2023-2024 | Carto 3 |
| Medtronic, INC. | $417.32 | 2021-2025 | Pulseselect, Ffrangio, Hawkone |
| Novartis Pharmaceuticals Corporation | $159.97 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $147.35 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $138.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.06 | 2020-2025 | Farxiga, Bevespi Aerosphere |
| Impulse Dynamics (USA) INC. | $95.12 | 2023-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $91.84 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $87.99 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.59 | 2019-2023 | Lifevest |
| Bridgebio Pharma, INC. | $72.93 | 2025 | Attruby |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $60.70 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $52.27 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $52.06 | 2023 | Assure Wcd |
| Amgen INC. | $41.09 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.27 | 2019-2024 | Jardiance |
| Preventice Services, LLC | $30.78 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.78 | 2019-2023 | |
| Zoll Respicardia, INC. | $25.73 | 2023 | Remede System |
| Lundbeck LLC | $21.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.87 | 2019 | |
| Merck Sharp & Dohme LLC | $14.64 | 2023 | Verquvo |
| Amarin Pharma, INC. | $14.43 | 2019 | |
| Elutia, INC. | $14.22 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ramicone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.